Sander J. Robins

TL;DR: Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level, suggesting that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.

TL;DR: The use of the 10 contemporary biomarkers that were studied adds only moderately to standard risk factors and only small increases in the ability to classify risk, as measured by the C statistic.

TL;DR: Concentrations of LDL-C achieved with gemfibrozil treatment predicted a significant reduction in CHD events in patients with low HDL-C levels, however, the change in HDL- C levels only partially explained the beneficial effect of gem fibroZil.

TL;DR: In men with CHD and a low high-density lipoprotein cholesterol level, gemfibrozil use was associated with a reduction in major cardiovascular events in persons with diabetes and in nondiabetic subjects with a high fasting plasma insulin level.

TL;DR: In this paper, a Cox proportional regression analysis was used to assess relative risks of all-cause dementia and Alzheimer disease according to baseline plasma levels, and showed that the top quartile of plasma PC DHA level was associated with a significant reduction in the risk of developing all cause dementia in the Framingham Heart Study.